MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
Go back to MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates| (NASDAQ: INKT) | Delayed: 10.55 -0.16 (1.49%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.71 | 52 Week High | $ | |||
| Open | $10.75 | 52 Week Low | $ | |||
| Day High | $11.40 | P/E | N/A | |||
| Day Low | $10.51 | EPS | $ | |||
| Volume | 10,363 | |||||



